Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 6/20 | 0.35 |
| ▸ | MTOR | P42345 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 4/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31485102 | 0.76 | ROCK1 (0.41) | ROCK1LPLLIPGIDO1TDO2 | |
| SCHEMBL30336517 | 0.75 | MAP3K12 (0.42) | MAP3K12MTORPIK3CA | |
| SCHEMBL30748906 | 0.74 | MAP3K12 (0.42) | MAP3K12MTORPIK3CA | |
| SCHEMBL18339649 | 0.74 | MAP3K12 (0.42) | MAP3K12MTORPIK3CA | |
| SCHEMBL15657536 | 0.72 | KDM4E (0.46) | ROCK1LPLLIPGIDO1TDO2 | |
| SCHEMBL30748919 | 0.72 | KDM4E (0.46) | ROCK1LPLLIPGIDO1TDO2 | |
| SCHEMBL25715171 | 0.71 | ALDH1A1 (0.44) | ROCK1LPLLIPGIDO1TDO2 | |
| SCHEMBL14241709 | 0.71 | ROCK1 (0.38) | ROCK1LPLLIPGIDO1TDO2 | |
| SCHEMBL25153282 | 0.70 | LPL (0.43) | LPLLIPGIDH1 | |
| SCHEMBL23291623 | 0.70 | ROCK1 (0.39) | ROCK1LPLLIPGIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4543887-A2 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | Arizona Board of Regents on behalf of The University of Arizona (US) | 2025-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382277-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | ROCK1 1977/4885LPL 4312/4885LIPG 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.